NCT00629226View on ClinicalTrials.gov

Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2010

Conditions
Head and Neck Cancer
Interventions
BIOLOGICAL

cetuximab

Given IV

DRUG

bortezomib

Given IV

DRUG

cisplatin

Given IV

RADIATION

intensity-modulated radiation therapy

Once daily, 5 days a week, for up to 8 weeks

Trial Locations (2)

15232

UPMC Cancer Centers, Pittsburgh

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00629226 - Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer | Biotech Hunter | Biotech Hunter